Literature DB >> 9043716

The effects of anticonvulsant drugs on NMDA-EPSP, AMPA-EPSP, and GABA-IPSP in the rat hippocampus.

G Y Ko1, L M Brown-Croyts, T J Teyler.   

Abstract

The effects of phenobarbital, phenytoin, and valproic acid on pharmacologically isolated NMDA-EPSP, AMPA-EPSP, and GABA-IPSPs were examined in rat hippocampal slices. Phenobarbital (0.05 mg/ml) had no effect on the NMDA-EPSP, but decreased the slope of the AMPA-EPSP by 13.4% and facilitated the GABA-IPSP slope by 77.12%. Phenytoin (0.02 mg/ml) had no effects on the NMDA-EPSP, AMPA-EPSP, or GABA-IPSP. Valproic acid (0.1 mg/ml) decreased the NMDA-EPSP slope by 14.3%, increased the GABA-IPSP slope by 54.34%, and had no effect on the AMPA-EPSP. These data suggest that the mechanisms of action of these anticonvulsant drugs may be via their actions on different neurotransmitter systems or ion channels.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9043716     DOI: 10.1016/s0361-9230(96)00268-7

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  8 in total

1.  Excitatory GABAergic signalling is associated with benzodiazepine resistance in status epilepticus.

Authors:  Richard J Burman; Joshua S Selfe; John Hamin Lee; Maurits van den Berg; Alexandru Calin; Neela K Codadu; Rebecca Wright; Sarah E Newey; R Ryley Parrish; Arieh A Katz; Jo M Wilmshurst; Colin J Akerman; Andrew J Trevelyan; Joseph V Raimondo
Journal:  Brain       Date:  2019-11-01       Impact factor: 13.501

Review 2.  Molecular targets for antiepileptic drug development.

Authors:  Brian S Meldrum; Michael A Rogawski
Journal:  Neurotherapeutics       Date:  2007-01       Impact factor: 7.620

Review 3.  Proof of concept trials in bipolar disorder and major depressive disorder: a translational perspective in the search for improved treatments.

Authors:  Rodrigo Machado-Vieira; Carlos A Zarate
Journal:  Depress Anxiety       Date:  2011-02-24       Impact factor: 6.505

Review 4.  Anticonvulsants for neuropathic pain syndromes: mechanisms of action and place in therapy.

Authors:  I W Tremont-Lukats; C Megeff; M M Backonja
Journal:  Drugs       Date:  2000-11       Impact factor: 9.546

Review 5.  Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders.

Authors:  Gerard Sanacora; Carlos A Zarate; John H Krystal; Husseini K Manji
Journal:  Nat Rev Drug Discov       Date:  2008-05       Impact factor: 84.694

6.  Chronic administration of valproic acid reduces brain NMDA signaling via arachidonic acid in unanesthetized rats.

Authors:  Mireille Basselin; Lisa Chang; Mei Chen; Jane M Bell; Stanley I Rapoport
Journal:  Neurochem Res       Date:  2008-05-07       Impact factor: 3.996

7.  Deep brain stimulation, histone deacetylase inhibitors and glutamatergic drugs rescue resistance to fear extinction in a genetic mouse model.

Authors:  Nigel Whittle; Claudia Schmuckermair; Ozge Gunduz Cinar; Markus Hauschild; Francesco Ferraguti; Andrew Holmes; Nicolas Singewald
Journal:  Neuropharmacology       Date:  2012-06-18       Impact factor: 5.250

Review 8.  Excitatory and inhibitory synaptic dysfunction in mania: an emerging hypothesis from animal model studies.

Authors:  Yeunkum Lee; Yinhua Zhang; Shinhyun Kim; Kihoon Han
Journal:  Exp Mol Med       Date:  2018-04-09       Impact factor: 8.718

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.